Gain Therapeutics, Inc. (GANX)
| Market Cap | 51.44M |
| Revenue (ttm) | 130,926 |
| Net Income (ttm) | -12.33M |
| Shares Out | 11.88M |
| EPS (ttm) | -1.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,723 |
| Open | 3.90 |
| Previous Close | 4.04 |
| Day's Range | 3.90 - 4.41 |
| 52-Week Range | 3.80 - 17.93 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 27.00 (+523.6%) |
| Earnings Date | n/a |
About GANX
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B,...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for GANX stock is "Strong Buy." The 12-month stock price forecast is 27.00, which is an increase of 523.56% from the latest price.
News
Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference
BETHESDA, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never b...
Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BETHESDA, Md., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites...
Gain Therapeutics Progresses Krabbe Disease Program and Provides Scientific Update
Data Show Statistically Significant Increases in GALC Enzyme and Depletion of Toxic Substrate Psychosine Data Show Statistically Significant Increases in GALC Enzyme and Depletion of Toxic Substrate Psy...
Gain Therapeutics to Participate at the Imagine AI + Healthcare Investor Summit
BETHESDA, Md., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never b...
Gain Therapeutics Presents Parkinson's Disease Preclinical Study Results at Society for Neuroscience Annual Meeting
Brain-penetrant structurally targeted allosteric regulators for glucocerebrosidase (GCase) show promising in vivo pharmacological activity in Parkinson's Disease animal model Brain-penetrant structurall...
Gain Therapeutics Stock Surges On Positive Preclinical Readout For Neurodegenerative Disease Drugs
Gain Therapeutics, Inc. (NASDAQ: GANX) shares were trading higher Wednesday after the company presented positive data on two of its lead compounds. What Happened: Bethesda, Maryland-based Gain announced...
Gain Therapeutics, Inc. Announces Breakthrough Pre-Clinical Data of Novel Small Molecules for the Treatment of Parkin...
Study results demonstrate first small molecule approach to significantly reduce phosphorylated and aggregated -synuclein and increase GCase protein levels with transport to the lysosomes in iPSC dopami...
Gain Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference
In-Person Dates: November 16 th -17 th Virtual Dates: November 18 th -19 th
Gain Therapeutics to Present at Upcoming Medical Conferences
- The Michael J. Fox Foundation's Parkinson's Disease Therapeutics Webinars -
Gain Therapeutics, Inc. Announces Appointment of Five Members to its Newly Formed Scientific Advisory Board (SAB)
Dr. Luca Benatti to Chair SAB Dr. Luca Benatti to Chair SAB
Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer
BETHESDA, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites...
Gain Therapeutics' SEE-Tx™ Platform Shows Increasing Evidence in Treating Diseases Caused by Protein Misfolding
Image by National Cancer Institute on Unsplash Medical and technological advancements are extending our lifespan. Unfortunately, as human life expectancy rises, so does the risk of people developing a d...
Gain Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
Conference Dates: September 27th-30th Conference Dates: September 27th-30th
Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
- Conference Dates: September 20 th -23 rd -
Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference
BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding site...
Why Gain Therapeutics Shares Are Trading Higher Today
Gain Therapeutics Inc (NASDAQ: GANX) are trading higher Wednesday after the company announced positive topline data in a patient-derived iPSC study evaluating STAR compounds as a treatment for Gaucher a...
Gain Therapeutics' Gaucher, Parkinson's Candidate Shows Potential In Patient-Derived iPSC Study
The topline data from a study conducted at the University of Maryland School of Medicine (UMSOM) by Gain Therapeutics Inc (NASDAQ: GANX) evaluating two lead Structurally Targeted Allosteric Regulators (...
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a ...
GT-02287and GT-02329 compounds display positive effects on GCase activity and related parameters --- Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and d...
Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BETHESDA, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding site...
Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update
Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology --- Granted Two Patents for Compounds that Stabilize G-Case for Gaucher's Disease and other Synucleinopathie...
Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference
BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel alloste...
Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment o...
Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lysosomal Storage Diseases Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lys...
Gain Therapeutics to Present at the Jefferies Virtual Healthcare Conference
BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric bin...
Gain Therapeutics to Participate in Upcoming Virtual Investor Conferences in May
BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric bin...
Gain Therapeutics, Inc. Reports First Quarter 2021 Financial Results
Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team --- Signed a multi-target collab...